Company Profile
Chugai Pharmaceutical provides the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and globally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq.
Its portfolio also includes Actemra for humanized anti-human IL-6 receptor monoclonal antibody, CellCept, an immunosuppressant, Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody, Evrysdi, a spinal muscular atrophy agent, Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody, Mircera, an erythropoiesis-stimulating agent, PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody, Tamiflu, an anti-influenza agent, and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody.
Founded in 1925 and headquartered in Chuo, Japan, the company was formerly known as Chugai Shinyaku Shokai before rebranding in January 1943. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.